The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio ...
Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock ...
Zacks Investment Research on MSN
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 14.9 billion for the third quarter of 2025, up 6% year over ...
Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed ...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...
Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...
Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company ...
Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage ...
Clinical Director of the National Institute of Drug Abuse Dr. Lorenzo Leggio, said GLP-1 drugs' effect on the brain can help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback